WuXi Biologics and Vertex Pharma have reached a licensing and research service agreement for innovative tri-specific TCE

AASTOCKS
2026.02.04 01:58

WuXi Biologics (02269.HK) announced that it has signed a licensing and research service agreement with Vertex Pharma (VRTX.US) for an "innovative trispecific T cell engager" (TCE). Vertex Pharma plans to use it for the treatment of B cell-mediated autoimmune diseases.

According to the terms of the agreement, Vertex Pharma will receive global exclusive development and commercialization rights for the trispecific TCE, which is in the preclinical stage and aims to treat B cell-mediated autoimmune diseases. WuXi Biologics will receive an upfront payment and is eligible for milestone payments related to development, registration, and sales, as well as sales commissions after the product is launched.

In addition, WuXi Biologics will provide integrated contract research and development services for its innovative TCE

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer